Fee Transmittal Form Fee Attached Fee Attached Amendment/Reply After Final Povisional Application Change of Correspondence Address Extension of Time Request Express Abandonment Request Information Disclosure Statement Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Mi	TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission	Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	Approved for use through 07/31/2006. OMB 0651-0031 atent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action of information unless it displays a valid OMB control number. 10/750,934 12/31/2003 Thomas E. TARARA 1615 UNASSIGNED 0101.00
Firm Name NEKTAR THERAPEUTICS Signature Printed name Michael J. Mazza	Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request X Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Act Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): PTO/SB/08A; PCT Search Report; 19 Cited References; and Return Receipt
CERTIFICATE OF TRANSMISSION/MAILING	Firm Name NEKTAR THERAPE Signature Printed name Michael J. Mazza Date 1/29/07	UTICS Thayy	eg. No. 30,775

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name Al

Anna Tran

Date

01/29/2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FEB U 2 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the application of: Thomas E. TARARA, et)

Atty. Docket No.: 0101.00

Application No.: 10/750,934

Examiner: UNASSIGNED

Filed: 12/31/2003

Group Art Unit: 1615

Title: PHARMACEUTICAL FORMULATION

WITH AN INSOLUBLE ACTIVE

AGENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22315 1450 on Jan. 29, 2007

Signed:

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 CFR §1.56, §1.97 and §1.98</u>

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08A may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

Attorney Docket No. 0101.00

	\boxtimes	months of the date of	entry o	ling date of a national application or an RCE; within three of the national stage as set forth in section 1.491 in an before the mailing date of a first Office action on the ars last);	
	Attach	ned is Check No in the	he amou	unt of <u>\$0</u> .	
	Please	charge the amount of	<u>\$</u> to	Deposit Account 500348	
\boxtimes	If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348.				
				Respectfully submitted,	
				NEKTAR THERAPEUTICS	
Dated:	1/2	19/07	Ву:	Michael J. Mazza Reg. No. 30,775	

NEKTAR THERAPEUTICS 150 Industrial Road San Carlos, CA 94070 (650) 631-3271

011	PE	Form PTO-1	449	Attorney's Docket No.		ilication Seria '50,934	ii NO.		
INFORMATION DISCLOSURE STATEMENT		Applicant(s)							
1		2		Thomas T					
(FEB 0 2 2007 W				Filing Date: Group Art Unit:					
(use several sheets if necessary) Examiner Ref. Date Document No.				12/31/03 1615					
TATAL	CHART		The state of the s	I.S. PATENT DOCUMENTS					
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropria	ta)	
Initials	No.	04/2003	6,546,929	Burr, et al.	 	<u> </u>	(ii appropria	ie)	
	2.	01/2003	6,503,480	Edwards, et al.	-				
	3.	04/2002	6,372,258	Platz, et al.	<u> </u>				
	4.	03/2002	6,358,530	Eljamal, et al.	 				
	5.	03/2002	6,357,490	Johnston, et al.	1				
	6.	07/2001	6,257,233	Burr, et al.		-			
	7.	06/2000	6,077,543	Gordon, et al.				-	
	8.	04/2000	6,051,256	Platz, et al.					
	9.	12/1999	6,001,336	Gordon					
············	10.	11/1999	5,985,309	Edwards, et al.					
	11.	11/1999	5,985,248	Gordon, et al.					
	12.	11/1999	5,976,574	Gordon					
	13.	02/1999	5,874,064	Edwards, et al.					
	14.	01/1999	5,858,410	Muller, et al.					
	15.	01/1999	5,855,913	Hanes, et al.					
	16.	07/1998	5,785,049	Smith, et al.					
	17.	04/1997	5,619,985	Ohki, et al.					
	18.	10/1995	5,458,135	Patton, et al.					
	19.	07/1989	4,846,876	Draber, et al.					
	20.	07/1982	4,338,931	Cavazza					
	21.	01/1981	4,247,066	Frost, et al.					
	22.	09/1978	4,114,615	Wetterlin					
	23.	06/2004	US 2004/0105820	Weers, et al.			07/2003		
	24.	02/2002	US 2002/0017295	Weers, et al. (abandoned)			06/2001		
					<u> </u>		ļ <u>.</u>		
						ļ	ļ		
	<u> </u>				1	<u> </u>	ļ		
	<u> </u>	<u> </u>					 		
	<u> </u>	<u> </u>			 _ _ _ 	<u> </u>	 		
	<u> </u>				-	 			
	<u> </u>		<u> </u>			<u> </u>	<u></u>		
EXAMINE	R:			DATE CONSIDERED:					

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

'If an asterisk is piaced beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier fliing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2214179 v1

Form PTO-1449		Attorney's Docket No. Application Serial No. 10/750,934						
INFO	RMATIC	N DISCLOS	SURE STATEMENT	Applicant(s) Thor	nas TARARA,	et al.		
(use several sheets if necessary)				Filing Date: Group Art Unit:				
			if necessary)	12/31/03	161			
	**		F0	REIGN PATENT DOCUMENTS	er. nvr		<u>, </u>	
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Transla YES	ition NO
	25.	02/2000	00/07572	WO				
	26.	12/2000	00/72904	WO				
	27.	11/2001	01/85136	WO				
	28.	11/2001	01/85137	WO				
	29.	09/2002	02/067902	wo				
	30.	10/2002	02/083220	wo				
-	31	01/1995	95/01221	wo				
	32.	09/1995	95/24183	WO				
	33.	11/1995	95/31479	WO				
	34.	01/1996	96/00610	WO				
	35.	10/1996	96/32096	WO				
	36.	10/1996	96/32149	wo				
	37.	08/1998	98/36825	WO				
	38.	04/1999	99/16419	WO				
	40.	04/1999	99/16420	WO				
	41.	04/1999	99/16421	WO		1/4		190
	42.	04/1999	99/16422	WO				
			Ar a sparrage statement	A. 14. 14. 14. 14. 14. 14. 14. 14. 14. 14			Control of the	· Phos.
Examiner Initials		Title				`		
	43.	Activity", I	Drug Delivery, Vol. 8, No.	Drying of Amphotericin B-Phospholip b. 3, pp. 143-147 (2001).				
	44.		spersible powders for i 14, 116.	nhalation applications", Innovations i	n Pharmaceutic	cal Technology	y, Vol. 1, No 	o. 7, pp.
		-						

EXAMINER:	DATE CONSIDERED:					
EXAMINER: initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in						
conformance and not considered. Include a copy of this form with next communication to applicant.						

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2214179 v1